FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. (“GTC”, Nasdaq: GTCB) reported today its financial results for the fourth quarter and year ended December 30, 2007. Revenues were $3.1 million for the fourth quarter of 2007, compared with $2.8 million in the fourth quarter of 2006. Revenues for 2007 more than doubled to $13.9 million, a $7.8 million increase from $6.1 million in 2006. Revenues increased primarily due to payments from LEO for the supply of ATryn® and the services provided to PharmAthene for the development of their Protexia® product.
